Brown Snake Envenomation Medication
- Author: David Cheng, MD; Chief Editor: Rick Kulkarni, MD more...
Medication Summary
The antidote for systemic envenomations by the brown snake is the equine-derived antivenin. In a study of 35 patients with severe brown snake envenomation, two thirds of the cases were neutralized with 5 ampules and 89% were neutralized with 10 ampules.[2] As with all equine-derived antivenins, anaphylaxis should be anticipated and treated if any allergic reactions occur. Pretreatment with antihistamines and corticosteroids should be included.
Hypotension should be treated with isotonic crystalloid infusions and vasopressors if blood pressure is refractory to fluids alone.
Tetanus toxoid should be given when indicated.
Cholinesterase inhibitors, such as edrophonium and neostigmine, may be given to palliate the neurological sequelae of the venom but should not replace definitive airway control.
Antivenin
Class Summary
Gives passive immunity to the venom and should be administered immediately if any signs of systemic toxicity are present.
Antivenin
According to the Antivenin Index, the monovalent form is not carried in the US but may be found in Australia (Commonwealth Serum Laboratories, Melbourne, Australia). The polyvalent antivenin may be obtained at the Bronx Zoo, but a local zoo may be contacted.
Skin testing before antivenin administration is not recommended because it may sensitize the individual to future antivenin use and will delay the administration of the antivenin. Antihistamines and subcutaneous epinephrine should be administered (if no contraindications are present) before giving the antivenin.
1 U neutralizes 0.01 mg venom in vitro.
Antihistamines
Class Summary
H1 and H2 blockers should be given to prevent immune mediated responses and may be continued for an additional 5 days or for as long as symptoms persist.
Diphenhydramine (Benadryl)
For symptomatic relief of symptoms caused by release of histamine in allergic reactions.
Cimetidine (Tagamet)
H2 antagonist that, when combined with an H1 type, may be useful in treating itching and flushing in anaphylaxis, pruritus, urticaria, and contact dermatitis that do not respond to H1 antagonists alone. Use this medication in addition to H1 antihistamines.
Chlorpheniramine (Chlor-Trimeton)
Competes with histamine or H1-receptor sites on effector cells in blood vessels and respiratory tract.
Corticosteroids
Class Summary
Should be employed when evidence of an allergy-mediated event is present. However, onset of action is approximately 4-6 h and has limited benefit in the initial acute treatment of the rapidly deteriorating anaphylactic patient. Nonetheless, corticosteroids may benefit patients with persistent bronchospasm or hypotension.
Methylprednisolone (Solu-Medrol)
Decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Prednisone (Deltasone, Orasone, Sterapred)
Used for the treatment of a variety of diseases including serum sickness in the outpatient setting. Prednisone is inactive and must be metabolized to the active metabolite prednisolone. The conversion may be impaired in patients with liver disease.
Bronchodilators
Class Summary
These agents have combined alpha- and beta-adrenergic agonist action and are the agents of first choice in the treatment of anaphylaxis.
An additional option in the management of persistent bronchospasm may be anticholinergic agents. These agents block the action of acetylcholine at parasympathetic sites in bronchial smooth muscle.
Epinephrine (Adrenalin, EpiPen)
DOC for treating anaphylactoid reactions. The alpha-agonist effects of epinephrine increase peripheral vascular resistance and reverse peripheral vasodilatation, vascular permeability, and systemic hypotension. Conversely, the beta-agonist effects produce bronchodilatation, positive inotropic and chronotropic cardiac activity, and result in an increased production of intracellular cAMP.
Albuterol (Ventolin, Proventil)
Beta-agonist useful in the treatment of bronchospasm that is refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta 2-receptors and has little effect on cardiac muscle contractility
Theophylline (Aminophylline, Theo-Dur, Slo-bid)
Potentiates exogenous catecholamines. Stimulates endogenous catecholamine release and diaphragmatic muscular relaxation, which in turn stimulates bronchodilation.
For bronchodilation, near toxic (>20 mg/dL) levels are usually required.
Ipratropium (Atrovent)
Chemically related to atropine. Has antisecretory properties and, when applied locally, inhibits secretions from serous and seromucous glands lining the nasal mucosa.
Cholinesterase inhibitors
Class Summary
May be useful in reversing neurological complications of the venom; however, they should not be a substitute for airway management.
Edrophonium (Enlon, Reversol, Tensilon)
Short active cholinesterase inhibitor that inhibits the destruction of acetylcholine by acetylcholinesterase and may palliate weakness. Facilitates transmission of impulses across myoneural junction and results in increased cholinergic responses (eg, miosis, increased tonus of intestinal and skeletal muscles, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland secretions).
Usually administered IV, but, if this is not possible, IM/SC route may be used.
Neostigmine (Prostigmin)
Longer acting cholinesterase inhibitor that can be used when edrophonium is ineffective. Inhibits destruction of acetylcholine by acetylcholinesterase, which facilitates transmission of impulses across myoneural junction.
Immune Globulin
Class Summary
Consists of administration of immunoglobulin pooled from serum of immunized subjects.
Tetanus immune globulin (TIG)
Used for passive immunization of any person with a wound that might be contaminated with tetanus spores.
O'Leary MA, Isbister GK, Schneider JJ, Brown SG, Currie BJ. Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming: detecting venom, antivenom and venom-antivenom complexes. Toxicon. Jul 2006;48(1):4-11. [Medline].
Yeung JM, Little M, Murray LM, Jelinek GA, Daly FF. Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years. Med J Aust. Dec 6-20 2004;181(11-12):703-5. [Medline].
Brown SG, Caruso N, Borland ML, McCoubrie DL, Celenza A, Isbister GK. Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy. Intensive Care Med. Sep 2009;35(9):1532-8. [Medline].
Isbister GK, Brown SG, MacDonald E, White J, Currie BJ. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis. Med J Aust. Apr 21 2008;188(8):473-6. [Medline].
Brimacombe J, Murray A. Envenomation by Ingram's Brown snake (Pseudonaja ingrami). Anaesth Intensive Care. Apr 1995;23(2):231-3. [Medline].
Broad AJ, Sutherland SK, Coulter AR. The lethality in mice of dangerous Australian and other snake venom. Toxicon. 1979;17(6):661-4. [Medline].
Buckley N, Dawson AH. Unusual results of brown snake envenomation. Med J Aust. Jun 21 1993;158(12):866-8. [Medline].
Currie BJ. Snakebite in tropical Australia: a prospective study in the "Top End" of the Northern Territory. Med J Aust. Dec 6-20 2004;181(11-12):693-7. [Medline].
Henderson A, Baldwin LN, May C. Fatal brown snake (Pseudonaja textilis) envenomation despite the use of antivenom. Med J Aust. May 17 1993;158(10):709-10. [Medline].
Hodgson WC. Pharmacological action of Australian animal venoms. Clin Exp Pharmacol Physiol. Jan 1997;24(1):10-7. [Medline].
Isbister GK, O'Leary MA, Schneider JJ, Brown SG, Currie BJ; ASP Investigators. Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies. Toxicon. Jan 2007;49(1):57-67. [Medline].
Masci PP, Mirtschin PJ, Nias TN, et al. Brown snakes (Pseudonaja genus): venom yields, prothrombin activator neutralization and implications affecting antivenom usage. Anaesth Intensive Care. Jun 1998;26(3):276-81. [Medline].
Munro JG, Pearn JH. Snake bite in children: a five year population study from South-East Queensland. Aust Paediatr J. Dec 1978;14(4):248-53. [Medline].
Pantanowitz L, Guidozzi F. Management of snake and spider bite in pregnancy. Obstet Gynecol Surv. Oct 1996;51(10):615-20. [Medline].
Ripamonti C, De Conno F, Boffi R, et al. Can somatostatin be administered in association with morphine in advanced cancer patients with pain?. Ann Oncol. Aug 1998;9(8):921-3. [Medline].
Schapel GJ, Utley D, Wilson GC. Envenomation by the Australian common brown snake--Pseudonaja (Demansia) textilis textilis. Med J Aust. Jan 16 1971;1(3):142-4. [Medline].
Sprivulis P, Jelinek GA. Fatal intracranial haematomas in two patients with Brown snake envenomation. Med J Aust. Feb 20 1995;162(4):215-6. [Medline].
Sutherland SK. Concern over the choice of antivenom for "false king brown snake" bites and a plea for a name change. Med J Aust. Feb 15 1999;170(4):187. [Medline].
Sutherland SK. Venomous Creatures of Australia. Oxford University Press; 1981.
Sutherland SK, Leonard RL. Snakebite deaths in Australia 1992-1994 and a management update. Med J Aust. Dec 4-18 1995;163(11-12):616-8. [Medline].
Tibballs J, Sutherland S, Kerr S. Studies on Australian snake venoms. Part 1: The haemodynamic effects of brown snake (Pseudonaja) species in the dog. Anaesth Intensive Care. Nov 1989;17(4):466-9. [Medline].
Tibballs J, Sutherland SK, Kerr S. Studies on Australian snake venoms, Part II: The haematological effects of brown snake (Pseudonaja) species in the dog. Anaesth Intensive Care. Aug 1991;19(3):338-42. [Medline].
Walter FG, Bilden EF, Gibly RL. Envenomations. Crit Care Clin. Apr 1999;15(2):353-86, ix. [Medline].
White J. Envenoming and antivenom use in Australia. Toxicon. Nov 1998;36(11):1483-92. [Medline].

